House dust mite sublingual immunotherapy: a double‐blind, placebo‐controlled study in elderly patients with allergic rhinitis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Background: Immunotherapy in elderly patients is controversial, and there is still no evidence supporting this treatment's safety and efficacy in this population. This study was performed to evaluate the safety and efficacy of specific sublingual immunotherapy for house dust mite (HDM) allergens in patients over 60 years of age with allergic rhinitis and a confirmed allergy to HDM. Objective: This study sought to assess nasal symptoms during HDM season, reduce medication use and monitor for adverse reactions during immunotherapy. Methods: One hundred and eleven 60‐ to 75‐year‐old patients with allergic rhinitis and a confirmed D ermatophagoides pteronyssinus and D ermatophagoides farinae allergy were included in the study. The patients were individually randomized to active or placebo groups using a double‐blind method (NCTO 01605760 ClinicalTrials.gov). A total of 51 subjects in the sublingual allergen‐specific immunotherapy (SLIT) group (S taloral 300 R, S tallergenes, F rance) and 57 subjects in the placebo group were monitored for 3 years. Results: Forty‐seven patients completed 3 years of SLIT, and 48 subjects finished the placebo treatment in the same time period. The total nasal symptom score decreased by 44% in the active group and 6% in the placebo group after 3 years of SLIT. This difference was only significant in the active group (P < 0.05). At the end of therapy, the total medication score of the active group decreased significantly by a maximum of 51% (P < 0.05), whereas the total medication score of the placebo control group showed an insignificant decrease (P = 0.56). There were no systemic adverse reactions during the study. Conclusions & Clinical Relevance: Sublingual allergen‐specific immunotherapy in elderly patients with a HDM allergy to D. pteronyssinus and D. farinae generated a significant clinical improvement in the active group compared with the placebo group, particularly during the heating season. This therapy was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Cited by
EAACI Guidelines on Allergen Immunotherapy: Allergic Rhinoconjunctivitis
Roberts, G., Pfaar, O., Akdis, C. A., Ansotegui, I. J., Durham, S. R., Gerth van Wijk, R., Halken, S., Larenas‐Linnemann, D., Pawankar, R., Pitsios, C., et al. (2018) · Allergy · doi:10.1111/all.13317 · Cited by 702
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Canonica, G. W., Cox, L., Pawankar, R., Baena-Cagnani, C. E., Blaiss, M., Bonini, S., Bousquet, J., Calderón, M., Compalati, E., Durham, S. R., et al. (2014) · World Allergy Organization Journal · doi:10.1186/1939-4551-7-6 · Cited by 591
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis
Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., et al. (2017) · Allergy · doi:10.1111/all.13201 · Cited by 369
Nolte, H., Maloney, J., Nelson, H. S., Bernstein, D. I., Lu, S., Li, Z., Kaur, A., Zieglmayer, P., Zieglmayer, R., Lemell, P., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1911 · Cited by 160
Metadata
- Authors
- Bozek, A., Ignasiak, B., Filipowska, B., & Jarzab, J.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2013-01-18
- Volume
- 43
- Issue
- 2
- Pages
- 242-248
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2023826256
- Cited by
- 107
- References
- 1
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.